212 related articles for article (PubMed ID: 31836708)
1. Functional significance of U2AF1 S34F mutations in lung adenocarcinomas.
Esfahani MS; Lee LJ; Jeon YJ; Flynn RA; Stehr H; Hui AB; Ishisoko N; Kildebeck E; Newman AM; Bratman SV; Porteus MH; Chang HY; Alizadeh AA; Diehn M
Nat Commun; 2019 Dec; 10(1):5712. PubMed ID: 31836708
[TBL] [Abstract][Full Text] [Related]
2. Wild-Type U2AF1 Antagonizes the Splicing Program Characteristic of U2AF1-Mutant Tumors and Is Required for Cell Survival.
Fei DL; Motowski H; Chatrikhi R; Prasad S; Yu J; Gao S; Kielkopf CL; Bradley RK; Varmus H
PLoS Genet; 2016 Oct; 12(10):e1006384. PubMed ID: 27776121
[TBL] [Abstract][Full Text] [Related]
3. U2AF1 mutation connects DNA damage to the alternative splicing of RAD51 in lung adenocarcinomas.
Chen C; Zhou P; Zhang Z; Liu Y
Clin Exp Pharmacol Physiol; 2022 Jul; 49(7):740-747. PubMed ID: 35434831
[TBL] [Abstract][Full Text] [Related]
4. Integrative Profiling of Alternative Splicing Induced by
Kim S; Park C; Jun Y; Lee S; Jung Y; Kim J
Mol Cells; 2018 Aug; 41(8):733-741. PubMed ID: 29991672
[TBL] [Abstract][Full Text] [Related]
5. Full-length transcript alterations in human bronchial epithelial cells with
Soulette CM; Hrabeta-Robinson E; Arevalo C; Felton C; Tang AD; Marin MG; Brooks AN
Life Sci Alliance; 2023 Oct; 6(10):. PubMed ID: 37487637
[No Abstract] [Full Text] [Related]
6. Mutant U2AF1-induced alternative splicing of H2afy (macroH2A1) regulates B-lymphopoiesis in mice.
Kim SP; Srivatsan SN; Chavez M; Shirai CL; White BS; Ahmed T; Alberti MO; Shao J; Nunley R; White LS; Bednarski J; Pehrson JR; Walter MJ
Cell Rep; 2021 Aug; 36(9):109626. PubMed ID: 34469727
[TBL] [Abstract][Full Text] [Related]
7. A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events.
Brooks AN; Choi PS; de Waal L; Sharifnia T; Imielinski M; Saksena G; Pedamallu CS; Sivachenko A; Rosenberg M; Chmielecki J; Lawrence MS; DeLuca DS; Getz G; Meyerson M
PLoS One; 2014; 9(1):e87361. PubMed ID: 24498085
[TBL] [Abstract][Full Text] [Related]
8. Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene
Fei DL; Zhen T; Durham B; Ferrarone J; Zhang T; Garrett L; Yoshimi A; Abdel-Wahab O; Bradley RK; Liu P; Varmus H
Proc Natl Acad Sci U S A; 2018 Oct; 115(44):E10437-E10446. PubMed ID: 30322915
[TBL] [Abstract][Full Text] [Related]
9. A splice site-sensing conformational switch in U2AF2 is modulated by U2AF1 and its recurrent myelodysplasia-associated mutation.
Warnasooriya C; Feeney CF; Laird KM; Ermolenko DN; Kielkopf CL
Nucleic Acids Res; 2020 Jun; 48(10):5695-5709. PubMed ID: 32343311
[TBL] [Abstract][Full Text] [Related]
10. Ribosome biogenesis is a downstream effector of the oncogenic U2AF1-S34F mutation.
Akef A; McGraw K; Cappell SD; Larson DR
PLoS Biol; 2020 Nov; 18(11):e3000920. PubMed ID: 33137094
[TBL] [Abstract][Full Text] [Related]
11. Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins.
Neel DS; Allegakoen DV; Olivas V; Mayekar MK; Hemmati G; Chatterjee N; Blakely CM; McCoach CE; Rotow JK; Le A; Karachaliou N; Rosell R; Riess JW; Nichols R; Doebele RC; Bivona TG
Cancer Res; 2019 Feb; 79(3):546-556. PubMed ID: 30538120
[TBL] [Abstract][Full Text] [Related]
12. U2AF1 mutations alter sequence specificity of pre-mRNA binding and splicing.
Okeyo-Owuor T; White BS; Chatrikhi R; Mohan DR; Kim S; Griffith M; Ding L; Ketkar-Kulkarni S; Hundal J; Laird KM; Kielkopf CL; Ley TJ; Walter MJ; Graubert TA
Leukemia; 2015 Apr; 29(4):909-17. PubMed ID: 25311244
[TBL] [Abstract][Full Text] [Related]
13. The splicing factor U2AF1 contributes to cancer progression through a noncanonical role in translation regulation.
Palangat M; Anastasakis DG; Fei DL; Lindblad KE; Bradley R; Hourigan CS; Hafner M; Larson DR
Genes Dev; 2019 May; 33(9-10):482-497. PubMed ID: 30842218
[TBL] [Abstract][Full Text] [Related]
14. U2AF1 mutation promotes tumorigenicity through facilitating autophagy flux mediated by FOXO3a activation in myelodysplastic syndromes.
Zhu Y; Song D; Guo J; Jin J; Tao Y; Zhang Z; Xu F; He Q; Li X; Chang C; Wu L
Cell Death Dis; 2021 Jun; 12(7):655. PubMed ID: 34183647
[TBL] [Abstract][Full Text] [Related]
15. Circular RNA F-circSR derived from SLC34A2-ROS1 fusion gene promotes cell migration in non-small cell lung cancer.
Wu K; Liao X; Gong Y; He J; Zhou JK; Tan S; Pu W; Huang C; Wei YQ; Peng Y
Mol Cancer; 2019 May; 18(1):98. PubMed ID: 31118036
[TBL] [Abstract][Full Text] [Related]
16. MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by
Sato H; Schoenfeld AJ; Siau E; Lu YC; Tai H; Suzawa K; Kubota D; Lui AJW; Qeriqi B; Mattar M; Offin M; Sakaguchi M; Toyooka S; Drilon A; Rosen NX; Kris MG; Solit D; De Stanchina E; Davare MA; Riely GJ; Ladanyi M; Somwar R
Clin Cancer Res; 2020 Jun; 26(12):2932-2945. PubMed ID: 32122926
[TBL] [Abstract][Full Text] [Related]
17. Aberrant Alternative Splicing in U2af1/Tet2 Double Mutant Mice Contributes to Major Hematological Phenotypes.
Martínez-Valiente C; Garcia-Ruiz C; Rosón B; Liquori A; González-Romero E; Fernández-González R; Gómez-Redondo I; Cervera J; Gutiérrez-Adán A; Sanjuan-Pla A
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34203454
[TBL] [Abstract][Full Text] [Related]
18. Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome.
Shirai CL; White BS; Tripathi M; Tapia R; Ley JN; Ndonwi M; Kim S; Shao J; Carver A; Saez B; Fulton RS; Fronick C; O'Laughlin M; Lagisetti C; Webb TR; Graubert TA; Walter MJ
Nat Commun; 2017 Jan; 8():14060. PubMed ID: 28067246
[TBL] [Abstract][Full Text] [Related]
19. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
Kato Y; Ninomiya K; Ohashi K; Tomida S; Makimoto G; Watanabe H; Kudo K; Matsumoto S; Umemura S; Goto K; Ichihara E; Ninomiya T; Kubo T; Sato A; Hotta K; Tabata M; Toyooka S; Maeda Y; Kiura K
Cancer Sci; 2018 Oct; 109(10):3149-3158. PubMed ID: 30053332
[TBL] [Abstract][Full Text] [Related]
20. CD74/SLC34A2-ROS1 Fusion Variants Involving the Transmembrane Region Predict Poor Response to Crizotinib in NSCLC Independent of TP53 Mutations.
Li W; Fei K; Guo L; Wang Y; Shu C; Wang J; Ying J
J Thorac Oncol; 2024 Apr; 19(4):613-625. PubMed ID: 38070598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
